Bioverativ, Inc.



$63.87Share Price
$6.9 BMarket Cap
6.3%EBIT / EV
6.6%FCF / EV
46.8%Cash ROIC
93.8%3yr Avg Revenue Growth
2.01Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

gray wandCurrent member of one or more spells! Log in to see which ones.
check mark The EBIT / Enterprise Value of 6.3% ranks as Above Average.
check mark The Free Cash Flow / Enterprise Value of 6.6% ranks as Very High.
check mark The Return on Invested Capital Value of 44.3% ranks as Very High.
check mark The Cash Return on Capital Value of 46.8% ranks as Very High.
check mark The 3 Year Average Revenue Growth Value of 93.8% ranks as Very High.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 2.01.

Company Description

Bioverativ engages in discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorder. Its product includes Eloctate and Alprolix. The company is headquartered in Cambridge, MA.


You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.
Tracking Portfolios
blue wand Magic Recipe 29.36%
purple wand Deep Value 24.71%
orange wand Quality Growth 44.22%
green wand Green Team 6.14%
red dot Red Rating 5.76%
yellow dot Yellow Rating 14.17%
green dot Green Rating 14.95%
New Spell Stocks
blue wand Vector Group Ltd. (VGR)
purple wand New Stocks Added!